Yes, inflammation can directly cause blood clots. The two systems, immune defense and blood clotting, share overlapping molecular pathways and actively amplify each other. This isn’t a loose association: people with high levels of C-reactive protein (CRP), a common blood marker of inflammation, have roughly 2.3 times the risk of developing a venous blood clot compared to people with low levels. Understanding how this works can help you recognize which inflammatory conditions raise your clot risk and what can be done about it.
How Inflammation Triggers Clotting
Your blood vessels are lined with a thin layer of cells called the endothelium. Under normal conditions, these cells produce nitric oxide, a molecule that relaxes blood vessels and prevents platelets from sticking together. The endothelium acts as a non-stick surface that keeps blood flowing smoothly.
When inflammation kicks in, immune signaling molecules like TNF-alpha and IL-6 damage that protective lining. The inflamed endothelial cells become “leaky and sticky,” losing their ability to produce nitric oxide while simultaneously displaying adhesion molecules on their surface. These adhesion molecules grab passing immune cells and platelets, pulling them out of the bloodstream and onto the vessel wall. At the same time, inflammatory signals cause both immune cells and damaged vessel walls to produce tissue factor, a protein that jumpstarts the clotting cascade. The result is a blood vessel that has gone from actively preventing clots to actively promoting them.
There’s also a more recently discovered mechanism involving white blood cells called neutrophils. When activated by infection or inflammation, neutrophils can expel their own DNA in web-like structures that act as a physical scaffold for clot formation. Red blood cells, platelets, and clotting proteins get caught in these webs, building up into a thrombus. This process helps trap invading bacteria, but it can also trigger dangerous clots in the wrong context.
The Feedback Loop Between Clotting and Inflammation
What makes this relationship particularly dangerous is that it runs in both directions. Inflammation promotes clotting, and clotting promotes more inflammation. Clotting factors and processes activate immune cells and control their behavior, which generates additional inflammatory signals, which further damage the vessel lining and trigger more clotting. This self-reinforcing cycle is why conditions involving chronic or severe inflammation can spiral into serious clotting events without an obvious injury to a blood vessel.
Chronic Conditions That Raise Clot Risk
Several inflammatory diseases carry a measurably higher risk of blood clots. Rheumatoid arthritis is one of the clearest examples. A large nationwide cohort study found that people with rheumatoid arthritis have a 3.36-fold increased risk of deep vein thrombosis (DVT) and a 2.07-fold increased risk of pulmonary embolism compared to the general population, even after adjusting for age, sex, and other health conditions. That elevated risk comes not from the joints themselves but from the systemic inflammation that defines the disease.
Other chronic inflammatory conditions associated with increased clot risk include inflammatory bowel disease (Crohn’s and ulcerative colitis), lupus, and psoriasis. The common thread is persistent, body-wide inflammation that keeps the endothelium in a damaged, pro-clotting state over months or years. Atherosclerosis, the buildup of plaques in arteries, is itself a chronic inflammatory process. When an inflamed plaque ruptures under the stress of blood flow, it exposes tissue factor directly to the bloodstream, which can trigger a clot large enough to cause a heart attack or stroke.
Cancer and Blood Clots
Cancer is another major driver of inflammation-related clotting. Tumors release inflammatory cytokines including TNF-alpha, CRP, and other signaling molecules that push the blood toward a clot-prone state. Research has shown that cancer patients with blood clots have markedly elevated levels of these inflammatory markers, and treating those patients with blood thinners significantly reduces those inflammatory signals. This strongly suggests that inflammation isn’t just a bystander in cancer-associated clots but a central part of the mechanism.
Sepsis: When Inflammation Overwhelms Clotting Control
The most extreme example of inflammation-driven clotting occurs in sepsis, a life-threatening response to infection. In the early stages of sepsis, the massive release of inflammatory signals pushes the body into a hypercoagulable state, meaning blood clots form too easily throughout the body. This is called sepsis-induced coagulopathy (SIC), and it’s recognized as a distinct condition with its own diagnostic criteria based on platelet count, clotting time, and organ function scores.
Doctors now screen for SIC early because catching it at this stage means the clotting changes are still reversible. If left unchecked, the condition progresses to disseminated intravascular coagulation (DIC), where widespread clotting throughout the body consumes so many clotting factors and platelets that the patient paradoxically shifts from clotting too much to bleeding uncontrollably. This late-stage shift is one of the most dangerous complications of severe infection.
CRP as a Clot Risk Indicator
C-reactive protein is produced by the liver in response to IL-6, one of the key inflammatory signaling molecules. It’s widely used as a general marker of inflammation, and its connection to clot risk is well established. Two large population studies from Copenhagen found a consistent dose-response relationship: the higher the CRP, the greater the clot risk.
CRP levels are typically categorized as low (under 1 mg/L), average (1 to 3 mg/L), or high (above 3 mg/L). People with levels above 3 mg/L had a 2.3 to 2.4-fold increased risk of venous thromboembolism compared to those below 1 mg/L. At the highest levels measured, the risk climbed to 3.4-fold. These associations held even when measured up to 16 years before the clotting event, suggesting that sustained low-grade inflammation raises clot risk over the long term, not just during acute flare-ups.
How Reducing Inflammation Lowers Clot Risk
Because inflammation and clotting are so tightly linked, treatments that reduce inflammation can independently lower clot risk. Statins are the best-studied example. While statins are prescribed primarily to lower cholesterol, they also restore endothelial function, reduce inflammatory cell activity in blood vessel walls, and lower CRP levels. Some of these protective effects appear before cholesterol levels even change, confirming they work through separate anti-inflammatory pathways.
Specifically, statins boost the endothelium’s production of nitric oxide, which inhibits platelet clumping and keeps vessels relaxed. Animal studies have shown that statin therapy directly reduces platelet buildup on damaged blood vessels and decreases clot formation. Statins also suppress the adhesion molecules that pull immune cells onto the vessel wall, interrupting the inflammatory cycle at one of its earliest steps. These effects help explain why the cardiovascular benefits of statins are larger than cholesterol reduction alone would predict.
For people with inflammatory diseases like rheumatoid arthritis, effective control of the underlying disease with anti-inflammatory or immune-modulating therapies also reduces clot risk. The principle is straightforward: less systemic inflammation means less endothelial damage, less tissue factor production, and a blood environment that’s less prone to inappropriate clotting. If you have a chronic inflammatory condition, keeping inflammation well controlled isn’t just about managing symptoms. It’s one of the most important things you can do to protect your cardiovascular system.